Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future.
Biologics
Biológicos
Fármacos de pequeña molécula
Hidradenitis suppurativa
Hidradenitis supurativa
Small molecule inhibitors
Journal
Actas dermo-sifiliograficas
ISSN: 1578-2190
Titre abrégé: Actas Dermosifiliogr
Pays: Spain
ID NLM: 0373062
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
18
04
2023
revised:
03
05
2023
accepted:
05
05
2023
medline:
5
10
2023
pubmed:
22
5
2023
entrez:
21
5
2023
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic inflammatory entity characterized by the appearance of multiple nodules, abscesses, and fistulas, predominantly in apocrine regions. In addition to its dermatological involvement, it is associated with multiple systemic comorbidities. Its treatment is combined: topical pharmacological, systemic pharmacological and surgical. Regarding biologic or small molecule drugs, currently only adalimumab is approved. A narrative review of the literature on biological or small molecule drugs used in the treatment of hidradenitis suppurativa is presented. The arsenal we found is large, with multiple targets: inhibitors of tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-17, IL-23, IL-1, inhibitors of the janus kinase (JAK) pathway, and multiple other drugs in study. New prospective studies and comparative trials are needed to analyze the effectiveness and safety of these treatments, in an entity with a promising future.
Identifiants
pubmed: 37211274
pii: S0001-7310(23)00355-1
doi: 10.1016/j.ad.2023.05.015
pii:
doi:
Substances chimiques
Adalimumab
FYS6T7F842
Tumor Necrosis Factor-alpha
0
Biological Products
0
Types de publication
Journal Article
Review
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
772-783Informations de copyright
Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.